Cargando…

Clinical and Economic Evaluation of Transdermal Oxybutynin in the Treatment of Overactive Bladder in Spain

Background: This study evaluated the clinical outcomes and economic results of transdermal oxybutynin compared to fesoterodine, tolterodine, solifenacin, oxybutynin, trospium chloride, and mirabegron for overactive bladder syndrome in Spain. Materials and Methods: A Markov model was built with month...

Descripción completa

Detalles Bibliográficos
Autores principales:	Crespo, Carlos, Blasco, Pedro, Guigini, Marcelo, Galván, Jordi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Columbia Data Analytics, LLC 2018
Materias:	Urological/Gynecological Diseases
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9090463/ https://www.ncbi.nlm.nih.gov/pubmed/35620774 http://dx.doi.org/10.36469/9811

Ejemplares similares

Transdermal oxybutynin in the treatment of overactive bladder
por: Davila, G Willy
Publicado: (2006)

Insights into the Management of Overactive Bladder with Transdermal Oxybutynin: A Practical Review
por: Vozmediano-Chicharro, Raúl, et al.
Publicado: (2020)

Efficacy of Transdermal Oxybutynin in the Treatment of Overactive Bladder Syndrome: Does It Make Sense Using It in 2017?
por: Vozmediano-Chicharro, Raúl, et al.
Publicado: (2018)

Patient perspectives in the management of overactive bladder, focus on transdermal oxybutynin
por: Gamble, Tondalaya, et al.
Publicado: (2008)

Elicitation of Health-related Quality-of-life Concepts Associated with Overactive Bladder: A Qualitative Study
por: Hawken, Natalia, et al.
Publicado: (2016)

Treatment Patterns for Patients on Overactive Bladder Therapy: A Retrospective Statistical Analysis Using Canadian Claims Data
por: Wagg, Adrian, et al.
Publicado: (2016)

Oxybutynin topical gel in the treatment of overactive bladder
por: Davila, G Willy
Publicado: (2010)

Development of oxybutynin chloride topical gel for overactive bladder
por: Lucente, Vincent R, et al.
Publicado: (2011)

Effects of oxybutynin transdermal system on health-related quality of life and safety in men with overactive bladder and prostate conditions
por: Staskin, D R, et al.
Publicado: (2008)

Clinical utility of transdermal delivery of oxybutynin gel via a metered-dose pump in the management of overactive bladder
por: Wagg, Adrian
Publicado: (2012)

Impact of depression on overactive bladder
por: Kawahara, Takashi, et al.
Publicado: (2020)

Oxybutynin extended release for the management of overactive bladder: a clinical review
por: Arisco, AM, et al.
Publicado: (2009)

Oxybutynin and Tolterodine in a Trial for Treatment of Overactive Bladder in Iranian Women
por: Aziminekoo, Elham, et al.
Publicado: (2014)

OnabotulinumtoxinA 100U provides significant improvements in overactive bladder symptoms in patients with urinary incontinence regardless of the number of anticholinergic therapies used or reason for inadequate management of overactive bladder
por: Sievert, K-D, et al.
Publicado: (2014)

Comparative assessment of onabotulinumtoxinA and mirabegron for overactive bladder: an indirect treatment comparison
por: Freemantle, Nick, et al.
Publicado: (2016)

Risk factors associated with the progression of overactive bladder among patients with type 2 diabetes
por: Zhu, Yiyi, et al.
Publicado: (2019)

Effects of flexible-dose fesoterodine on overactive bladder symptoms and treatment satisfaction: an open-label study
por: Wyndaele, J-J, et al.
Publicado: (2009)

Practical aspects of lifestyle modifications and behavioural interventions in the treatment of overactive bladder and urgency urinary incontinence
por: Wyman, J F, et al.
Publicado: (2009)

Potential benefits of diagnosis and treatment on health outcomes among elderly people with symptoms of overactive bladder
por: Lee, L. K., et al.
Publicado: (2015)

Cardiovascular safety in refractory incontinent patients with overactive bladder receiving add‐on mirabegron therapy to solifenacin (BESIDE)
por: Drake, Marcus J., et al.
Publicado: (2017)

A novel approach to overactive bladder syndrome treatment
por: Szalecki, Paweł
Publicado: (2014)

Mechanism of traditional Chinese medicine in treating overactive bladder
por: Liao, Yuxiang, et al.
Publicado: (2022)

Efficacy and safety of fesoterodine 8 mg in subjects with overactive bladder after a suboptimal response to tolterodine ER
por: Kaplan, S A, et al.
Publicado: (2014)

Adherence and persistence of mirabegron and anticholinergic therapies in patients with overactive bladder: a real‐world claims data analysis
por: Sussman, D., et al.
Publicado: (2017)

Real-world persistence and adherence to oral antimuscarinics and mirabegron in patients with overactive bladder (OAB): a systematic literature review
por: Yeowell, Gillian, et al.
Publicado: (2018)

Travel Burden and the Direct Medical Costs of Urologic Surgery
por: Olson, Daniel J., et al.
Publicado: (2016)

Cost-Effectiveness and Budget Impact of Emerging Minimally Invasive Surgical Treatments for Benign Prostatic Hyperplasia
por: Chughtai, Bilal, et al.
Publicado: (2021)

A Time-motion Comparison of Itemized Treatment Costs in First and Second In Vitro Fertilization Attempts: A United Kingdom Fertility Centre Experience
por: Jones, Christopher A., et al.
Publicado: (2013)

Relationship between overactive bladder and irritable bowel syndrome: a large-scale internet survey in Japan using the overactive bladder symptom score and Rome III criteria
por: Matsumoto, Seiji, et al.
Publicado: (2013)

Cost-Utility Analysis of Oxybutynin vs. OnabotulinumtoxinA (Botox) in the Treatment of Overactive Bladder Syndrome
por: Shabir, Habiba, et al.
Publicado: (2021)

A Novel Metered Dose Transdermal Spray Formulation for Oxybutynin
por: Bakshi, A., et al.
Publicado: (2008)

Injectable, Adhesive, and Self-Healing Composite Hydrogels Loaded With Oxybutynin Hydrochloride for the Treatment of Overactive Bladder in Rats
por: Sun, Peng, et al.
Publicado: (2022)

Sleep disturbance changes in women after treatment of refractory overactive bladder with sacral neuromodulation
por: Sanderson, Derrick J., et al.
Publicado: (2020)

Mirabegron for the treatment of overactive bladder: a prespecified pooled efficacy analysis and pooled safety analysis of three randomised, double-blind, placebo-controlled, phase III studies
por: Nitti, V W, et al.
Publicado: (2013)

Predictive Factors for High Post-void Residual Volume in Older Females After OnabotulinumA Treatment for Severe Overactive Bladder Using a Machine Learning Model
por: Okui, Nobuo, et al.
Publicado: (2023)

Editorial Comment: Combination therapy in overactive bladder-untapped research opportunities: A systematic review of the literature
por: Riccetto, Cássio L. Z.
Publicado: (2021)

Friction underwear for ease of pulling down in elderly patients with overactive bladder: A prospective randomized control trial
por: You, Jae Hyung, et al.
Publicado: (2019)

Tolterodine Tartrate Proniosomal Gel Transdermal Delivery for Overactive Bladder
por: Rajabalaya, Rajan, et al.
Publicado: (2016)

Efficacy and safety of intradetrusor onabotulinumtoxinA injection for managing paediatric non-neurogenic overactive bladder: A prospective case-series study
por: El-Dakhakhny, Amr S., et al.
Publicado: (2019)

Posterior tibial nerve stimulation as treatment for the overactive bladder
por: Sherif, Hammouda, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_134b7nmfsnpom4gobad85kdtj8